Article Details


Dihydromyricetin Reduces TGF-β Via P53 Activation-dependent Mechanism in Hepatocellular Carcinoma HepG2 Cells

[ Vol. 24 , Issue. 5 ]

Author(s):

Xiaojie Huang, Tianming Lian, Xiaoqian Guan, Bin Liu, Siyuan Hao, Jingjing Zhang, Shiting Bao, Xiaoyu Tan and Runzhi Zhu   Pages 419 - 424 ( 6 )

Abstract:


Natural antineoplastic drug development is crucial to treatment of clinical oncology. Dihydromyricetin, a bioactive flavonoid compound was extracted from the stems and leaves of Ampelopsis grossedentata. It exhibited anticancer activity and induced apoptosis in human hepatocellular carcinoma cells according to our previous studies. In this study, we demonstrated that DHM could significantly inhibit proliferation and induce apoptosis in HepG2 cells with MTT and Flow Cytometry methods. It is very interesting that we found DHM could regulate TGF-β signal pathway and which has a crosstalk with P53, Smad3 and P-Smad2/3 proteins. Meanwhile, we confirmed that DHM showed antitumor activity by regulating the activation of the p53-dependent pathways (MDM2, P-MDM2, BAX and Bcl-2). These findings defined and supported a novel mechanism that DHM could induce cell apoptosis by reducing TGF-β via p53 signal pathway in HepG2 cells.

Keywords:

Dihydromyricetin, anti-cancer, proliferation, apoptosis, P53, hepatocellular carcinoma.

Affiliation:

Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease, Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease, Dalian Medical University, 9 West Section, Lvshun South Road, Dalian 116044, Pharmacy College, Jinan University, Guangzhou 510632, Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease, Clinical Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease, Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease, Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease and Clinical Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001

Graphical Abstract:



Read Full-Text article